Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.

ABSTRACT:

Background

Colorectal cancer (CRC) is increasingly prevalent among young adults (<50 years) in China, a demographic that has been historically underrepresented in clinical studies. While most patients with CRC are aged ⩾65 years, this age group is also underrepresented in trials, highlighting the need for a better understanding of treatment outcomes in both younger and older populations. A recent phase IV trial evaluating the safety of fruquintinib in Chinese patients with metastatic CRC (mCRC) showed a manageable profile.

Objectives

This subgroup analysis of the phase IV study primarily aims to evaluate the safety of fruquintinib in different age groups.

Design

Prospective real-world study.

Methods

The data of patients with CRC from the phase IV fruquintinib t

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12402659 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature